70/100BIllumina company profile
- CEO
- Jacob Thaysen
- Employees
- 8,600
- Headquarters
- 5200 Illumina Way, San Diego, CA 92122, US
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- IPO date
- 28 Jul 2000
- Stock exchange
- NASDAQ
- ISIN
- US4523271090
Website:illumina.com
About the company
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
Employees
Illumina had about 8,600 employees at the end of fiscal year 2025 (28 December 2025), by its annual report. That is 4.1% fewer than a year before.
Employees at each fiscal year end, as the company reports them in its annual report (10-K); revenue and net income per employee are the fiscal year's over that count.
Who owns Illumina
Institutions such as funds, banks and insurers held 102.7% of Illumina's shares on 30 June 2026, 974 of them reporting holdings to the SEC; the rest is held by individual investors and other shareholders.
Shares free to trade
Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.
How Illumina pays its executives
The chief executive was paid 11.02M USD for fiscal 2025, 80% of it in shares and options.
| Name and position | Salary | Bonus | Stock awards | Cash incentive | Other pay | Total pay |
|---|---|---|---|---|---|---|
| Jacob Thaysen Chief Executive Officer | 1.00M USD | — | 8.76M USD | 1.16M USD | 100.77K USD | 11.02M USD |
| Everett Cunningham Former Chief Commercial Officer | 650.00K USD | 500.00K USD | 2.87M USD | — | 65.88K USD | 4.09M USD |
| Ankur Dhingra Chief Financial Officer | 650.00K USD | — | 3.09M USD | 325.33K USD | 10.67K USD | 4.08M USD |
| Steve Barnard Chief Technology Officer | 600.00K USD | — | 2.56M USD | 300.30K USD | 17.68K USD | 3.48M USD |
| Kevin Pegels Chief of Global Operations | 575.00K USD | — | 2.30M USD | 287.79K USD | 20.20K USD | 3.18M USD |
FY2025 · From the company's proxy statements to the SEC: what each named executive was paid for the fiscal year, shares and options at their value when granted. The latest filing
Common questions about Illumina
Source: Financial Modeling Prep